ArticleCureus2026
Giant Pancreatic Acinar Cell Carcinoma: A Case Report and Review of Molecular Pathogenesis and Emerging Therapies.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic acinar cell carcinoma (ACC) is a rare pancreatic malignancy with molecular and clinical features distinct from pancreatic ductal adenocarcinoma (PDAC). We report a 58-year-old man with a 15-cm ACC of the pancreatic body and tail treated by distal pancreatectomy and splenectomy. Complete resection was achieved despite tumor size and surface fissuring suggestive of impending rupture. Operative time was 282 minutes with blood loss of 280 mL. Histopathology showed acinar architecture with B-cell lymphoma 10 (Bcl-10) positivity and nuclear beta-catenin accumulation, consistent with Wnt pathway activation. To clarify the biological differences between ACC and PDAC, we compared their molecular and clinicopathological features. Our analysis demonstrates that ACC's unique molecular profile and growth characteristics enabled successful surgical resection in this giant tumor. This case illustrates how systematic comparison of ACC with PDAC provides insights into the distinct biological behaviors of these pancreatic malignancies. We review current therapeutic advances in PDAC, including targeted therapies and immunotherapy approaches, which may inform future treatment strategies for ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.